LAG3 Antikörper (AA 300-500)
Kurzübersicht für LAG3 Antikörper (AA 300-500) (ABIN7873639)
Target
Alle LAG3 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 300-500
-
Verwendungszweck
- Lymphocyte activation gene 3 Antibody / LAG3 / CD223
-
Aufreinigung
- Protein A/G affinity
-
Immunogen
- A recombinant partial protein sequence (within amino acids 300-500) from the human protein was used as the immunogen for the Lymphocyte activation gene 3 antibody.
-
Isotyp
- IgG1, kappa
-
-
-
-
Applikationshinweise
- Optimal dilution of the Lymphocyte activation gene 3 antibody should be determined by the researcher.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 0.2 mg/mL
-
Buffer
- 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Aliquot the Lymphocyte activation gene 3 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- LAG3 (Lymphocyte-Activation Gene 3 (LAG3))
-
Andere Bezeichnung
- Lymphocyte activation gene 3
-
Hintergrund
- LAG-3 (also called CD223) is a high affinity MHC class II ligand present on the surface of CD4+CD8+ T cells and NK cell, with shared homology in structure to CD4 Molecules. It has a glutamic acid-proline (EP) repetitive sequence found in other functionally distinct mammalian, parasitic, and bacterial proteins that may influence a conserved biological function. LAG-3+CD4+CD8+ T cells can associate with the T cell receptor (TCR) and downregulate TCR signaling in vitro. LAG-3 inhibits CD4-dependent T cell function via its cytoplasmic domain. LAG-3 Lys-468 within a conserved KIEELE motif is essential for interaction with downstream signaling molecules. Furthermore, as a checkpoint inhibitor target, it may be superior to CTLA-4 and PD-1 since both antibodies only activate effector T-cells, whereas an antagonist LAG-3 antibody can both activate T effector cells (by downregulating the LAG-3 inhibiting signal into pre-activated LAG-3+ cells) and inhibit induced (i.e. antigen-specific) Treg suppressive activity.
-
UniProt
- P18627
-
Pathways
- Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints
Target
-